Received Jul 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Shingrix administered in the buttocks; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of vaccine administered at inappropriate site in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccine administered at inappropriate site (Verbatim: Shingrix administered in the buttocks). The outcome of the vaccine administered at inappropriate site was not applicable. Additional Information: GSK Receipt Date: 24-JUN-2025 As per Web form received on June 24th 2025, the pharmacist reported that they had a patient who had receive theirs in the buttocks at the physician's office which led to vaccine administered at inappropriate site. The pharmacist enquired was it ok or preferred to administer the Shingrix vaccine in the buttocks. The pharmacist mentioned that they were told deltoid is preferred since this is where it was studied in clinical trials.